Additionally, FGF2 led to an increase in CSL (cancer stemness-like) /Live (live CSL cells versus all live cells) in all four cell lines, with a greater increase in the FGFR1 amplified cells (463.5 ± 86.7% in CAMA1 and 305.2 ± 20.5% in MDA-MB-134) compared to non-amplified cells (169.4 ± 42.2% in MCF7 and 172.3 ± 34.1%in T47D) (Fig. 7A). The gene discussed is FGF2; the disease is cancer.